The vicious vortex doesn’t wait. Neither should you. Prescribe now.

SmartVest®
Break The Cycle:

Clear Airways FirstTM

Bronchiectasis can be unrelenting. Once the vicious vortex begins, it only accelerates. New drugs may help reduce inflammation but they don’t clear mucus. And without airway clearance, inflammation and infection can continue to spiral.

The SmartVest® Airway Clearance System is a clinically proven solution designed to disrupt the vicious vortex at its source.

By clearing the airways first, SmartVest® improves quality of life1 and helps preserve lung health2,  making it the essential first step in any multimodal treatment plan.

Most patients meet the criteria. Most still don’t get the therapy.

According to a recent analysis of the U.S. Bronchiectasis and NTM Research Registry (BRR):3

58%

Of qualifying patients did not receive high frequency chest wall oscillation (HFCWO) therapy.3

Qualifying patients not prescribed HFCWO had a higher incidence of asthma, COPD, shortness of breath, and cough.3

During the three-year follow-up, 13% of patients not prescribed HFCWO at baseline later received it—and were found to be more clinically unstable, with higher rates of exacerbations, hospitalizations, and antibiotic use3

Evidence shows introduction of SmartVest® HFCWO improves patient outcomes.1

SmartVest® helps stabilize lung function, reduce the need for antibiotics and emergency care, and improve patients’ quality of life.1

  • 57%
    reduction in antibiotic use1
  • 60%
    reduction in emergency visits1
  • 59%
    reduction in hospitalizations1
  • 68%
    reported improved quality of life1
Read the Study

Don’t wait for multiple exacerbations. Protect lung health from the start.

Letting mucus persist puts patients at risk. An early SmartVest® prescription can help. When your bronchiectasis patient presents with a chronic productive cough, frequent respiratory infections, or visible mucus on imaging, it’s time to intervene.

With a bronchiectasis diagnosis, chronic productive cough lasting 6+ months, and tried-and-failed documentation, SmartVest® can be prescribed immediately.

Start Prescribing SmartVest®

The case for targeting mucus buildup.

New medication offers a promising approach to reduce inflammation but it doesn’t address the mucus buildup that drives the vicious vortex of infection, inflammation, and irreversible lung damage.4

SmartVest® works where medication alone cannot—clearing mucus that traps bacteria and worsens symptoms. By removing this fuel source, SmartVest helps reduce the risk of exacerbations and gives your patients a more complete path to long-term stability.2

SmartVest® 2 *Medication4
Clears Mucus✔️❌
Improves Sputum Expulsion✔️❌
Reduces Infection Risk✔️✔️
Reduces Inflammation❌✔️

SmartVest® patients report real relief and the real-world data reflects it.

Studies and patient data show consistent benefits in both outcome measures and satisfaction:

  • 97%

    report feeling better after using SmartVest*

  • 99%

    report improved ability to expel sputum*

  • 81%

    report less rescue inhaler use*

  • 94%

    would recommend SmartVest*

SmartVest device designed to expel mucus build-up

Don’t settle for an incomplete solution.

Stop the vortex. Treat smart from the start.

Start Prescribing SmartVest® Today
Complete Bronchiectasis Care
References
  1. Sievert C et al. Respiratory Therapy. 2016;11(4):34-38.
  2. Powner J, et al. BMC Pulm Med. 2019;19(1):82.
  3. Feir C et al. World Bronchiectasis Conference Abstract Book. 2025; 226.
  4. Chalmers JD, Burgel PR, Daley CL, et al. Phase 3 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2025;392(16):1569–1581. doi:10.1056/NEJMoa2411664
  5. Dekoven M et al. Am J Respir Crit Care Med. 2022;205:A3090.
  6. DeKoven M et al. IQVIA PharMetrics Plus for MedTech; 2018–2019.* Patient data on file.

©SmartVest is a registered trademark of Electromed, Inc.